CN100500221C - 用于眼科药物递送的生物可侵蚀膜剂 - Google Patents

用于眼科药物递送的生物可侵蚀膜剂 Download PDF

Info

Publication number
CN100500221C
CN100500221C CNB038167921A CN03816792A CN100500221C CN 100500221 C CN100500221 C CN 100500221C CN B038167921 A CNB038167921 A CN B038167921A CN 03816792 A CN03816792 A CN 03816792A CN 100500221 C CN100500221 C CN 100500221C
Authority
CN
China
Prior art keywords
fatty acid
film
film composition
coo
oocc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038167921A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668278A (zh
Inventor
B·P·卡布拉
J·D·豪伊
Y·田
D·A·马尔什
G·格拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1668278A publication Critical patent/CN1668278A/zh
Application granted granted Critical
Publication of CN100500221C publication Critical patent/CN100500221C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038167921A 2002-07-15 2003-06-30 用于眼科药物递送的生物可侵蚀膜剂 Expired - Fee Related CN100500221C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39584002P 2002-07-15 2002-07-15
US60/395,840 2002-07-15
US43272102P 2002-12-12 2002-12-12
US60/432,721 2002-12-12

Publications (2)

Publication Number Publication Date
CN1668278A CN1668278A (zh) 2005-09-14
CN100500221C true CN100500221C (zh) 2009-06-17

Family

ID=30118549

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038167921A Expired - Fee Related CN100500221C (zh) 2002-07-15 2003-06-30 用于眼科药物递送的生物可侵蚀膜剂

Country Status (17)

Country Link
US (1) US8084054B2 (enExample)
EP (1) EP1521572B1 (enExample)
JP (1) JP4454019B2 (enExample)
KR (1) KR101003514B1 (enExample)
CN (1) CN100500221C (enExample)
AT (1) ATE424187T1 (enExample)
AU (1) AU2003247671B2 (enExample)
CA (1) CA2491312C (enExample)
CY (1) CY1109606T1 (enExample)
DE (1) DE60326455D1 (enExample)
DK (1) DK1521572T3 (enExample)
ES (1) ES2321083T3 (enExample)
MX (1) MXPA05000631A (enExample)
PL (1) PL206379B1 (enExample)
PT (1) PT1521572E (enExample)
SI (1) SI1521572T1 (enExample)
WO (1) WO2004006889A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609432A2 (pt) * 2005-03-21 2010-04-06 Macusight Inc sistemas de distribuição de fármacos para tratamento de doenças ou condições
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
MX2013001116A (es) * 2010-07-29 2013-06-05 Santen Pharma Co Ltd Cuerpo para soporte de farmaco, y metodo para producir el mismo.
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
EP2600812B1 (en) 2010-08-05 2021-09-22 ForSight Vision4, Inc. Apparatus to treat an eye
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
JPWO2012153870A1 (ja) * 2011-05-11 2014-07-31 帝人株式会社 緑内障治療材
US20120302954A1 (en) * 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
EP2755600B1 (en) 2011-09-16 2021-03-17 ForSight Vision4, Inc. Fluid exchange apparatus
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP6385423B2 (ja) 2013-03-28 2018-09-05 フォーサイト・ビジョン フォー・インコーポレーテッド 治療物質送達用の眼移植片
ES2992100T3 (es) 2014-07-15 2024-12-09 Forsight Vision4 Inc Dispositivo de administración de implante ocular
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
CN113069681B (zh) 2015-11-20 2022-12-23 弗赛特影像4股份有限公司 制造用于缓释药物递送的治疗装置的方法
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
AU2023345389A1 (en) * 2022-09-23 2025-04-17 Madd Ophthalmics Ltd. Mucoadhesive drug delivery systems and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322319A2 (en) * 1987-12-22 1989-06-28 Oculex, Inc. Composition comprising biodegradable ocular implants
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
CN1171270A (zh) * 1996-05-06 1998-01-28 阿迪尔公司 用于控制释放活性组分的稳定亲脂基质为主要组分的药物组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042766B2 (ja) 1978-12-09 1985-09-25 日本化薬株式会社 基剤
GB8524421D0 (en) 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
SK279279B6 (sk) 1991-05-13 1998-09-09 The Boots Company Plc S(-)-nátrium-2-(4-izobutylfenyl)propionát-dihydrát
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6063116A (en) 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
RU2086218C1 (ru) 1995-07-26 1997-08-10 Санкт-Петербургская медицинская академия последипломного образования Способ лечения глаукомы
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DK1023050T3 (da) 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
ES2204531T3 (es) * 1999-03-16 2004-05-01 Merck Patent Gmbh Composicion que comprende isoquercetina y acido ascorbico en una forma de liberacion sostenida.
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
US6306120B1 (en) 1999-06-07 2001-10-23 Ben Gee Tan Applicator and method for delivery of mitomycin to eye tissues during glaucoma filtering surgery
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322319A2 (en) * 1987-12-22 1989-06-28 Oculex, Inc. Composition comprising biodegradable ocular implants
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
CN1171270A (zh) * 1996-05-06 1998-01-28 阿迪尔公司 用于控制释放活性组分的稳定亲脂基质为主要组分的药物组合物

Also Published As

Publication number Publication date
SI1521572T1 (sl) 2009-06-30
CA2491312A1 (en) 2004-01-22
MXPA05000631A (es) 2005-03-31
PL206379B1 (pl) 2010-08-31
KR101003514B1 (ko) 2010-12-30
CA2491312C (en) 2011-05-31
PT1521572E (pt) 2009-04-21
US8084054B2 (en) 2011-12-27
AU2003247671B2 (en) 2008-02-14
WO2004006889A1 (en) 2004-01-22
CN1668278A (zh) 2005-09-14
JP4454019B2 (ja) 2010-04-21
EP1521572A1 (en) 2005-04-13
EP1521572B1 (en) 2009-03-04
AU2003247671A1 (en) 2004-02-02
KR20050025961A (ko) 2005-03-14
ATE424187T1 (de) 2009-03-15
JP2005533106A (ja) 2005-11-04
ES2321083T3 (es) 2009-06-02
PL374764A1 (en) 2005-10-31
CY1109606T1 (el) 2014-08-13
DE60326455D1 (de) 2009-04-16
US20040126408A1 (en) 2004-07-01
DK1521572T3 (da) 2009-05-04

Similar Documents

Publication Publication Date Title
CN100500221C (zh) 用于眼科药物递送的生物可侵蚀膜剂
ZA200410095B (en) Bioerodible film for ophthalmic drug delivery
JP5582680B2 (ja) 生分解性チロシンキナーゼインヒビター硝子体内インプラント
TWI481423B (zh) 眼內藥物輸送系統
TWI377956B (en) Biodegradable intravitreal tyrosine kinase implants
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP5485314B2 (ja) ２ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
JP2009535422A (ja) 血管作動薬を含有する持続放出性眼内インプラント
JP2010513555A (ja) 眼内使用のための環状脂質インプラントの製造法
JP2007535564A (ja) 抗興奮毒性剤持続放出眼内インプラントおよび関連方法
AU2016269432A1 (en) Biodegradable introcular tyrosine kinase inhibitor implants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090617

Termination date: 20120630